email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2638-5945

Open Access Journal of Oncology and Medicine

Review Article(ISSN: 2638-5945)

Checkpoint Inhibitors in Squamous Non-Small Cell Lung Cancer (NSCLC)

Volume 2 - Issue 3

Bakulesh Khamar*

  • Author Information Open or Close
    • R&D Department, Cadila Pharmaceuticals Limited, Ahmedabad, India

    *Corresponding author: Bakulesh Khamar, Cadila Pharmaceuticals Limited, Cadila Corporate Campus Sarkhej-Dholka Road, Bhat, Ahmedabad, Gujarat, India

Received: August 08, 2018;   Published: August 14, 2018

DOI: 10.32474/OAJOM.2018.02.000140

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Checkpoint inhibitors have demonstrated efficacy in squamous NSCLC with tolerable toxicity profile. They are used as a monotherapy, in combination with chemotherapy or following chemo-radiotherapy as a first line, second line or consolidation therapy. As a first line, Pembrolizumab improves outcome (PFS) as a monotherapy in patients with PD-L1 expression of ≥ 50% (HR; 0.35). When used with chemotherapy, it improves PFS (HR; 0.56) irrespective of PD-L1 expression level. Nivolumab also improves PFS (HR; 0.62), when used as a second line for those progressing with chemotherapy. Durvalumab improves PFS (HR; 0.68) when used following chemo-radio therapy as a consolidation therapy.

Keywords: Checkpoint Inhibitors; Pembrolizumab; Nivolumab; Atezolizumab; Durvalumab; PD-L1; Squamous NSCLC; Progression Free Survival; Overall Survival

Abstract| Introduction| Checkpoint inhibitors as a Consolidation therapy| Checkpoint Inhibitors as a Second Line Therapy| Checkpoint Inhibitors as a Third Line Therapy| Checkpoint Inhibitors and Management of Squamous NSCLC- Recent Advances| Conclusion| References|